Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study - The Lancet Oncology

Immunotherapy and Targeted Therapies in the Treatment of Non-small Cell Lung Cancer - touchONCOLOGY

Pharmaceutics, Free Full-Text

Molecularly directed therapy of advanced/metastatic non-small cell lung cancer (CME article)

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial, BMC Cancer

PDF) Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)

Frontiers Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer

Current and Future Therapeutics for Patients with Non-small Cell Lung Cancer and Known Activating Mutations in Epidermal Growth Factor Receptor - touchONCOLOGY

Emerging evidence and treatment paradigm of non-small cell lung cancer, Journal of Hematology & Oncology

Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR - eBioMedicine

PDF) Erlotinib in the treatment of advanced non-small cell lung cancer: An update for clinicians

PDF) Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report